Liraglutide for Metabolic Syndrome
This trial is studying whether exercise, liraglutide, or both can improve cardiac and skeletal muscle function in people with Metabolic Syndrome.
- Metabolic Syndrome
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Side effects dataFrom 2017 Phase 4 trial • 100 Patients • NCT02014740
Awards & Highlights
Find a site
Who is running the clinical trial?
Frequently Asked Questions
Am I eligible to participate in this research?
"This research program is looking to enrol 80 individuals with metabolic syndrome between 21 and 60 years old. To qualify, they must have an increased waist circumference (≥102 cm in men; ≥88 cm in women), BMI >25 and ≤35 kg/m2, triglycerides at least 150 mg/dl, HDL-cholesterol under 40mg/dl for males or 50 mg/dl for females, systolic blood pressure of 130 mmHg or higher OR diastolic blood pressure 85mmHg+, fasting glucose levels greater than 100 mg/dL, and be on stable doses of ACE inhibitors and beta blockers for a"
Is the cutoff age for eligibility in this trial beyond eighty years?
"The qualifications for this study restrict applicants to those between 21 and 60 years old. By contrast, there are 388 trials available for minors, while 1070 exist for seniors."
Is this research experiment currently enrolling participants?
"Clinicaltrials.gov declares that this clinical trial is actively searching for participants, with the initial posting made on November 1st 2020 and most recently updated July 15th 2022."
What conditions does Liraglutide typically serve to ameliorate?
"Liraglutide is an effective therapeutic option for those suffering from exercise-induced symptoms, inadequate control on monotherapy treatments, and cardiovascular risk reduction."
How large is the population sample size for this research undertaking?
"Affirmative. Clinicaltrials.gov archives demonstrate that this trial, which was first publicized on November 1st 2020, is currently recruiting individuals for participation. 80 subjects are required to be enrolled from one medical centre."
Has the U.S. Food and Drug Administration given its stamp of approval to Liraglutide?
"There is ample evidence suggesting liraglutide's safety, thus it was given a score of 3 on our scale. This treatment has already been approved and released to the public in this Phase 4 trial."